Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer
Autor: | Eric M. Anderson, Albert C. Koong, Jeffrey A. Norton, Jonathan S. Pai, George A. Poultsides, Margaret M. Kozak, Brendan C. Visser, Rie von Eyben, Daniel T. Chang |
---|---|
Rok vydání: | 2016 |
Předmět: |
Male
0301 basic medicine Oncology Time Factors endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment Kaplan-Meier Estimate California 0302 clinical medicine Endocrinology Risk Factors Aged 80 and over Middle Aged Pancreaticoduodenectomy Stanford Cancer Institute Metformin humanities Treatment Outcome 030220 oncology & carcinogenesis Pancreatectomy Female Carcinoma Pancreatic Ductal medicine.drug Adult medicine.medical_specialty Statin medicine.drug_class Risk Assessment Disease-Free Survival 03 medical and health sciences Internal medicine Pancreatic cancer Internal Medicine medicine Humans Aged Proportional Hazards Models Retrospective Studies Hepatology Proportional hazards model business.industry nutritional and metabolic diseases Retrospective cohort study Protective Factors medicine.disease digestive system diseases Surgery Pancreatic Neoplasms 030104 developmental biology Multivariate Analysis Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
Zdroj: | Pancreas. 45:64-70 |
ISSN: | 0885-3177 |
Popis: | The aim of this study was to investigate the impact of statin and metformin therapy on disease outcome for patients with pancreatic ductal adenocarcinoma (PDAC).This retrospective study included 171 PDAC patients who underwent surgical resection at the Stanford Cancer Institute between 1998 and 2013. No patients received neoadjuvant therapy. Statin and metformin use was defined as use during initial consult and continuing upon discharge from the hospital after surgery. Dose of each medication was recorded, as was the type of statin taken.The median follow-up for all patients was 11.23 months (range, 0.2-105.0 months). Among the 171 patients included in our analysis, 18 patients (10.5%) took metformin and 34 patients (19.9%) took statins. Statin use was associated with better overall survival (OS) in patients with PDAC (P = 0.011). Metformin use was also associated with better OS (P = 0.035). The use of statins remained significant on multivariate analysis for OS (P = 0.014; hazards ratio, 0.33; 95% confidence interval, 0.139-0.799), but metformin use did not (P = 0.33; hazards ratio 0.60, 95% confidence interval, 0.211-1.675).Statin and metformin use is associated with improved OS in patients with resectable PDAC. These medications should be further investigated for possible long-term use in the general population. |
Databáze: | OpenAIRE |
Externí odkaz: |